Sie suchten nach: therapies (Portugiesisch - Englisch)

shire human genetic therapies ab vasagatan 7
shire human genetic therapies ab, vasagatan 7

riz shire human genetic therapies ab Åldermansgatan 2
shire human genetic therapies ab

titular da autorização de introdução no mercado shire orphan therapies gmbh
marketing authorisation holder shire orphan therapies gmbh friedrichstrasse 149

shire human genetic therapies ab Åldermansgatan 2, box 1117, 221 04 lund suécia
shire human genetic therapies ab Åldermansgatan 2, box 1117, 221 04 lund sweden

o fabricante é shire human genetic therapies ab, Åldermansgatan 2, p. o.
the manufacturer is shire human genetic therapies ab, Åldermansgatan 2, p. o.

fabricanteshire human genetic therapies ab, Åldermansgatan 2, box 1117, 221 04 lund, suécia
manufacturer shire human genetic therapies ab, Åldermansgatan 2, box 1117, 221 04 lund, sweden

however, flotation therapy is compatible with other therapies as a preparation or conjunct activity.
however, flotation therapy is compatible with other therapies as a preparation or conjunct activity.

shire human genetic therapies ab, Åldermansgatan 2, po box 1117, se 221 04 lund, suécia
shire human genetic therapies ab, Åldermansgatan 2, po box 1117, se 221 04 lund, sweden

synthetic peptide nucleic acid oligomers have been used in recent years in molecular biology procedures, diagnostic assays and antisense therapies.
synthetic peptide nucleic acid oligomers have been used in recent years in molecular biology procedures, diagnostic assays, and antisense therapies.

==== mortality ====nitrazepam therapy compared with other drug therapies increases risk of death when used for intractable epilepsy in an analysis of 302 patients.
"====mortality====nitrazepam therapy, compared with other drug therapies, increases risk of death when used for intractable epilepsy in an analysis of 302 patients.

o fabricante é shire human genetic therapies ab, Åldermansgatan 2, p.o. box 1117, se-221 04 lund, suécia.
the manufacturer is shire human genetic therapies ab, Åldermansgatan 2, p.o. box 1117 se-221 04 lund, sweden.

em 11 de julho de 2008, a comissão europeia concedeu à shire orphan therapies gmbh uma autorização de introdução no mercado, válida para toda a união europeia, para o medicamento firazyr.
the european commission granted a marketing authorisation valid throughout the european union for firazyr to shire orphan therapies gmbh on 11 july 2008.

outras informações sobre o elaprase em 8 de janeiro de 2007, a comissão europeia concedeu à shire human genetic therapies ab uma autorização de introdução no mercado, válida para toda a união europeia, para o medicamento elaprase.
other information about elaprase:the european commission granted a marketing authorisation valid throughout the european union for elaprase to shire human genetic therapies ab on 8 january 2007.

shire human genetic therapies ab, rinkebyvägen 11b, se 182 36 danderyd, suécia tel.: +46 8 5449 6400 fax: +46 8 5449 6429
shire human genetic therapies ab, rinkebyvägen 11b, se 182 36 danderyd, sweden tel: +46 8 5449 6400 fax: +46 8 5449 6429

== obras ==* "lehrbuch der hautkrankheiten" (1878 with ferdinand von hebra)* "pathologie und therapie der hautkrankheiten in vorlesungen für praktische Ärzte und studierende" (1880)* "pathologie und therapie der syphilis" (1881)* "handatlas der hautkrankenheiten" (1879)* "idiopathisches multiples pigmentsarkom der haut" (1872) arch dermatol syph 4:265-73 (artigo original em que descreve o sarcoma de kaposi).
==works==* "lehrbuch der hautkrankheiten" (1878 with ferdinand von hebra)* "pathologie und therapie der hautkrankheiten in vorlesungen für praktische Ärzte und studierende" (1880)* "pathologie und therapie der syphilis" (1881)* "handatlas der hautkrankenheiten" (1879)* "idiopathisches multiples pigmentsarkom der haut" (1872) arch dermatol syph 4:265-73 (original article describing kaposi's sarcoma)* english translation of article describing kaposi's sarcoma: kaposi m. idiopathic multiple pigmented sarcoma of the skin.